The COHCCC strongly supports the design and implementation of investigator-initiated clinical trials that test novel therapeutic agents developed at our institution and innovative applications of currently available agents. Protocol Specific Research Support (PSRS) continues to play an important role in providing preliminary data for extramurally funded proposals. All PSRS-eligible studies are reviewed and approved by the Protocol Review and Monitoring System (PRMS) as described in the PRMS Section. PSRS funding provides the Cancer Center with ongoing support for highly qualified clinical research personnel whose efforts on eligible studies are allocated through the Clinical Trials Office. Funded personnel help manage and ensure the success of protocols by providing a broad range of services in the areas of subject recruitment, data and specimen collection, and protocol compliance. Protocol prioritization and PSRS budget oversight is performed within the clinical research programs themselves and approved by the Center's Deputy Director for Clinical Research. Funding is requested for an appropriate portion of salary support for clinical research nurses, clinical research associates (CRAs), and study coordinators for work supporting PSRS-eligible trials.

Public Health Relevance

The overall goal of Protocol-Specific Research Support is the provision of funding for research nurses and data managers directly involved in the conduct of PSRS-eligible trials. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-31
Application #
8764856
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
31
Fiscal Year
2014
Total Cost
$93,576
Indirect Cost
$37,875
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Choi, Audrey H; O'Leary, Michael P; Chaurasiya, Shyambabu et al. (2018) Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. Surgery 163:336-342
Golfetto, Ottavia; Wakefield, Devin L; Cacao, Eliedonna E et al. (2018) A Platform To Enhance Quantitative Single Molecule Localization Microscopy. J Am Chem Soc 140:12785-12797
Aldoss, Ibrahim; Stiller, Tracey; Tsai, Ni-Chun et al. (2018) Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica 103:1662-1668
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
He, Zhiheng; Zhang, Jing; Huang, Zhaofeng et al. (2018) Sumoylation of ROR?t regulates TH17 differentiation and thymocyte development. Nat Commun 9:4870
Tirughana, Revathiswari; Metz, Marianne Z; Li, Zhongqi et al. (2018) GMP Production and Scale-Up of Adherent Neural Stem Cells with a Quantum Cell Expansion System. Mol Ther Methods Clin Dev 10:48-56
Raz, Dan J; Wu, Geena X; Consunji, Martin et al. (2018) The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography. Clin Lung Cancer 19:51-57
Solomon, Ilana; Rybak, Christina; Van Tongeren, Lily et al. (2018) Experience Gained from the Development and Execution of a Multidisciplinary Multi-syndrome Hereditary Colon Cancer Family Conference. J Cancer Educ :
Wang, Dongrui; Aguilar, Brenda; Starr, Renate et al. (2018) Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight 3:

Showing the most recent 10 out of 1396 publications